Thus, according to the current guidelines of the National Comprehensive Cancer Network (NCCN), immunotherapy is not recommended for the treatment of NSCLC patients together with EGFR inhibitors [37,38,39]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.